10x Genomics (1KJ) Stock Forecast & Price Target
1KJ Analyst Ratings
Moderate Buy
6Buy10Hold0Sell
Based on 16 analysts giving stock ratings to 10x Genomics in the past 3 months
1KJ Stock 12 Month Forecast
Average Price Target
EUR 67.81▲(16.00% Upside)Based on 16 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is EUR 67.81 with a high forecast of EUR 98.49 and a low forecast of EUR 44.77. The average price target represents a 16.00% change from the last price of EUR 58.46.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 98.49
AverageEUR 67.81
LowEUR 44.77
Highest Price TargetHighestEUR 98.49Average Price TargetEUR 67.81Lowest Price TargetLowestEUR 44.77
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mason Carrico | Stephens | EUR 58.20 | hold | -0.44%Downside | Downgraded | 10/23/26 | ||
| Casey Woodring | J.P. Morgan | EUR 44.77→EUR 62.68 | hold | 7.21%Upside | Reiterated | 10/16/26 | ||
| Kallum Titchmarsh | Morgan Stanley | EUR 35.82→EUR 62.68 | hold | 7.21%Upside | Assigned | 10/13/26 | ||
| Daniel Brennan | TD Cowen | EUR 42.08→EUR 62.68 | hold | 7.21%Upside | Reiterated | 10/13/26 | ||
| Kyle Mikson CFA | Canaccord Genuity | EUR 53.72→EUR 89.54 | buy | 53.16%Upside | Reiterated | 10/12/26 | ||
| Avantika Dhabaria | Bank of America Securities | EUR 44.77→EUR 71.63 | hold | 22.53%Upside | Reiterated | 10/09/26 | ||
| Luke Sergott | Barclays | EUR 46.56→EUR 98.49 | buy | 68.48%Upside | Reiterated | 10/07/26 | ||
| Puneet Souda | Leerink Partners | EUR 35.82→EUR 80.59 | hold | 37.85%Upside | Reiterated | 09/29/26 | ||
| Matt Larew | William Blair | ― | buy | ― | Reiterated | 09/29/26 | ||
| David Westenberg | Piper Sandler | EUR 42.08→EUR 71.63 | hold | 22.53%Upside | Assigned | 09/28/26 | ||
| John Eade | Argus Research | EUR 98.49 | buy | 68.48%Upside | Initiated | 09/25/26 | ||
 Unknown AnalystNot Ranked | UBS | EUR 17.91→EUR 60.89 | hold | 4.15%Upside | Initiated | 09/08/26 | ||
| Dan Leonard | RBC Capital | EUR 62.68 | hold | 7.21%Upside | Initiated | 09/01/26 | ||
| Daniel Arias | Stifel Nicolaus | EUR 44.77 | buy | -23.42%Downside | Reiterated | 08/11/26 | ||
| Brendan Digan | Citi | EUR 40.29→EUR 44.77 | hold | -23.42%Downside | Reiterated | 08/07/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Mason Carrico | 10/23/26 | EUR 58.20 | hold | -0.44%Downside | Downgraded | Stephens | ||
| Casey Woodring | 10/16/26 | EUR 44.77→EUR 62.68 | hold | 7.21%Upside | Reiterated | J.P. Morgan | ||
| Kallum Titchmarsh | 10/13/26 | EUR 35.82→EUR 62.68 | hold | 7.21%Upside | Assigned | Morgan Stanley | ||
| Daniel Brennan | 10/13/26 | EUR 42.08→EUR 62.68 | hold | 7.21%Upside | Reiterated | TD Cowen | ||
| Kyle Mikson CFA | 10/12/26 | EUR 53.72→EUR 89.54 | buy | 53.16%Upside | Reiterated | Canaccord Genuity | ||
| Avantika Dhabaria | 10/09/26 | EUR 44.77→EUR 71.63 | hold | 22.53%Upside | Reiterated | Bank of America Securities | ||
| Luke Sergott | 10/07/26 | EUR 46.56→EUR 98.49 | buy | 68.48%Upside | Reiterated | Barclays | ||
| Puneet Souda | 09/29/26 | EUR 35.82→EUR 80.59 | hold | 37.85%Upside | Reiterated | Leerink Partners | ||
| Matt Larew | 09/29/26 | ― | buy | ― | Reiterated | William Blair | ||
| David Westenberg | 09/28/26 | EUR 42.08→EUR 71.63 | hold | 22.53%Upside | Assigned | Piper Sandler | ||
| John Eade | 09/25/26 | EUR 98.49 | buy | 68.48%Upside | Initiated | Argus Research | ||
| Unknown AnalystNot Ranked | 09/08/26 | EUR 17.91→EUR 60.89 | hold | 4.15%Upside | Initiated | UBS | ||
| Dan Leonard | 09/01/26 | EUR 62.68 | hold | 7.21%Upside | Initiated | RBC Capital | ||
| Daniel Arias | 08/11/26 | EUR 44.77 | buy | -23.42%Downside | Reiterated | Stifel Nicolaus | ||
| Brendan Digan | 08/07/26 | EUR 40.29→EUR 44.77 | hold | -23.42%Downside | Reiterated | Citi |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering 10x Genomics
3 Months
Success Rate16/28 ratings generated profit
57%
Average Return
+13.74%
Copying Kyle Mikson CFA's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +13.74% per trade.
1 Year
Success Rate13/24 ratings generated profit
54%
Average Return
+65.46%
Copying Daniel Arias's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +65.46% per trade.
2 Years
Success Rate18/28 ratings generated profit
64%
Average Return
+164.48%
Copying Kyle Mikson CFA's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +164.48% per trade.
1KJ Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 7 | 12 | 11 | 12 | 4 |
| Hold | 14 | 12 | 16 | 14 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 21 | 24 | 27 | 26 | 13 |
In the current month, 1KJ has received 4 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. 1KJ average Analyst price target in the past 3 months is 67.81.
1KJ Financial Forecast
HighEUR -0.16
ConsensusEUR -0.24
LowEUR -0.30
1KJ Earnings Forecast
Next quarter’s earnings estimate for 1KJ is -EUR 0.24 with a range of -EUR 0.30 to -EUR 0.16. The previous quarter’s EPS was -EUR 0.13. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 136M
ConsensusEUR 132M
LowEUR 131M
1KJ Sales Forecast
Next quarter’s sales forecast for 1KJ is EUR 132.30M with a range of EUR 130.81M to EUR 136.08M. The previous quarter’s sales results were EUR 135.04M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1KJ Stock Forecast FAQ
What is DE:1KJ’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics’s 12-month average price target is €67.81.
What is DE:1KJ’s upside potential, based on the analysts’ average price target?
10x Genomics has 16.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is 10x Genomics a Buy, Sell or Hold?
10x Genomics has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 10 hold ratings and 0 sell ratings.
What is 10x Genomics’s share price target?
The average share price target for 10x Genomics is €67.81. This is based on 16 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €98.49, and the lowest forecast is €44.77. The average share price target represents a 16.00% increase from the current price of €58.46.
What do analysts say about 10x Genomics?
10x Genomics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Street analysts.
How can I buy shares of 10x Genomics?
To buy shares of DE:1KJ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
